- Home
- MGTX vs CYBN Comparison
MGTX vs CYBN Comparison
Compare MGTX & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGTX
- CYBN
- Stock Information
- Founded
- MGTX 2015
- CYBN 2019
- Country
- MGTX United States
- CYBN Canada
- Employees
- MGTX N/A
- CYBN N/A
- Industry
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- CYBN Pharmaceuticals and Biotechnology
- Sector
- MGTX Health Care
- CYBN Health Care
- Exchange
- MGTX Nasdaq
- CYBN Nasdaq
- Market Cap
- MGTX 302.6M
- CYBN 270.5M
- IPO Year
- MGTX N/A
- CYBN N/A
- Fundamental
- Price
- MGTX $3.88
- CYBN $0.21
- Analyst Decision
- MGTX Strong Buy
- CYBN Strong Buy
- Analyst Count
- MGTX 2
- CYBN 2
- Target Price
- MGTX $22.50
- CYBN $5.00
- AVG Volume (30 Days)
- MGTX 207.0K
- CYBN 6.4M
- Earning Date
- MGTX 08-12-2024
- CYBN 08-08-2024
- Dividend Yield
- MGTX N/A
- CYBN N/A
- EPS Growth
- MGTX N/A
- CYBN N/A
- EPS
- MGTX N/A
- CYBN N/A
- Revenue
- MGTX $8,122,000.00
- CYBN N/A
- Revenue This Year
- MGTX $133.83
- CYBN N/A
- Revenue Next Year
- MGTX $655.34
- CYBN N/A
- P/E Ratio
- MGTX N/A
- CYBN N/A
- Revenue Growth
- MGTX 26.87
- CYBN N/A
- 52 Week Low
- MGTX $3.49
- CYBN $0.17
- 52 Week High
- MGTX $7.60
- CYBN $0.74
- Technical
- Relative Strength Index (RSI)
- MGTX 39.37
- CYBN 14.06
- Support Level
- MGTX $3.87
- CYBN $0.17
- Resistance Level
- MGTX $4.28
- CYBN $0.27
- Average True Range (ATR)
- MGTX 0.19
- CYBN 0.02
- MACD
- MGTX -0.02
- CYBN -0.00
- Stochastic Oscillator
- MGTX 5.77
- CYBN 36.30
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds and protocols as potential treatments for various psychiatric and neurological conditions.